Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
<p>Validation cohort, patient flow diagram. Patient enrollment and final inclusion of FFPE tissue samples in this study is shown. n = 3 patients were excluded from enrollment for reasons listed. The validation cohort comprised paired tissue samples from a total of n = 38 patients. Detailed cha...
Збережено в:
Схожі ресурси
Схожі ресурси
-
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
за авторством: Sied Kebir (15048732)
Опубліковано: (2025) -
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
за авторством: Sied Kebir (15048732)
Опубліковано: (2025) -
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
за авторством: Sied Kebir (15048732)
Опубліковано: (2025) -
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
за авторством: Sied Kebir (15048732)
Опубліковано: (2025) -
Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
за авторством: Qingsheng Xu (17078830)
Опубліковано: (2025)